AIxMed

AIxMed has developed an AI-driven digital cytology platform that digitizes cytology samples rapidly and extracts clinical insights in seconds. The technology is designed to improve accuracy, efficiency, and workflow in cancer diagnostics—especially for bladder and cervical cancers—with lung cancer solutions forthcoming. Clinical results emphasize improved turnaround times, consistency with standards like The Paris System for Reporting Urinary Cytology, enhanced detection of abnormal cells, and streamlined reporting into EHRs. No traditional drug trial results are reported as the company is focused on diagnostics rather than therapeutics.